GlobeNewswire: Somaxon Pharmaceuticals, Inc. Contains the last 10 of 13 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T06:17:06ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2013/02/05/521096/10020662/en/Somaxon-Pharmaceuticals-Announces-Settlement-of-Silenor-Patent-Litigation-With-Actavis.html?f=22&fvtc=4&fvtv=16016Somaxon Pharmaceuticals Announces Settlement of Silenor Patent Litigation With Actavis2013-02-05T21:30:00Z<![CDATA[SAN DIEGO, Feb. 5, 2013 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that it has entered into a settlement agreement with Actavis Elizabeth LLC and Actavis Inc. to resolve pending patent litigation involving Silenor® 3 mg and 6 mg tablets.]]>https://www.globenewswire.com/news-release/2012/12/17/512103/10015828/en/Somaxon-Announces-That-Paladin-Labs-Has-Received-Approval-of-New-Drug-Submission-for-Silenor-R-in-Canada.html?f=22&fvtc=4&fvtv=16016Somaxon Announces That Paladin Labs Has Received Approval of New Drug Submission for Silenor (R) in Canada2012-12-17T21:35:00Z<![CDATA[SAN DIEGO, Dec. 17, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX) today announced that its licensee Paladin Labs Inc. (TSX:PLB) has received approval from Health Canada of Paladin's New Drug Submission (NDS) for Silenor]]>https://www.globenewswire.com/news-release/2012/12/11/510741/10015215/en/Pernix-Therapeutics-Announces-Agreement-to-Acquire-Somaxon-Pharmaceuticals-Inc.html?f=22&fvtc=4&fvtv=16016Pernix Therapeutics Announces Agreement to Acquire Somaxon Pharmaceuticals, Inc.2012-12-11T12:00:00Z<![CDATA[Somaxon Shareholders to Receive $25 Million in Pernix Common Stock
Pernix Management to Host a Conference Call Today at 9:00 a.m. EST]]>Somaxon Pharmaceuticals, Inc. Logohttps://www.globenewswire.com/news-release/2012/10/31/501478/10010458/en/Somaxon-Pharmaceuticals-Reports-Third-Quarter-2012-Financial-Results.html?f=22&fvtc=4&fvtv=16016Somaxon Pharmaceuticals Reports Third Quarter 2012 Financial Results2012-10-31T20:00:00Z<![CDATA[Conference call scheduled today at 4:30 p.m. ET (1:30 p.m. PT);
Simultaneous webcast at http://investors.somaxon.com/eventdetail.cfm]]>https://www.globenewswire.com/news-release/2012/10/22/498768/10009272/en/Somaxon-Pharmaceuticals-to-Report-Third-Quarter-2012-Results-and-Conduct-Conference-Call-on-Wednesday-October-31.html?f=22&fvtc=4&fvtv=16016Somaxon Pharmaceuticals to Report Third Quarter 2012 Results and Conduct Conference Call on Wednesday, October 312012-10-22T20:30:00Z<![CDATA[SAN DIEGO, Oct. 22, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that it will release its financial results for the third quarter ended September 30, 2012 on Wednesday, October 31, 2012 after the close of the U.S. financial markets. The Company will also conduct a conference call that same afternoon at 4:30 p.m. ET (1:30 p.m. PT) to discuss results and highlights of the third quarter of 2012.]]>https://www.globenewswire.com/news-release/2012/10/11/496549/10007976/en/Somaxon-Pharmaceuticals-Approves-1-for-8-Reverse-Stock-Split-and-Decrease-in-the-Number-of-Authorized-Shares-of-Its-Common-Stock-to-25-000-000-Shares.html?f=22&fvtc=4&fvtv=16016Somaxon Pharmaceuticals Approves 1-for-8 Reverse Stock Split and Decrease in the Number of Authorized Shares of Its Common Stock to 25,000,000 Shares2012-10-11T12:05:00Z<![CDATA[SAN DIEGO, Oct. 11, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that its Board of Directors approved a 1-for-8 reverse stock split of its common stock and a decrease in the number of authorized shares of its common stock from 100,000,000 to 25,000,000 shares. The reverse stock split and the decrease in the number of authorized shares of common stock were authorized by Somaxon's stockholders at a special meeting held on October 5, 2012. The reverse stock split will become effective as of 5:00 p.m. Pacific Time on October 11, 2012 and Somaxon's shares will trade on a post-split basis beginning on October 12, 2012. The new CUSIP number for Somaxon's common stock will be 834453 201.]]>https://www.globenewswire.com/news-release/2012/08/27/487165/10003050/en/Somaxon-Pharmaceuticals-to-Present-at-the-Stifel-Nicolaus-2012-Healthcare-Conference.html?f=22&fvtc=4&fvtv=16016Somaxon Pharmaceuticals to Present at the Stifel Nicolaus 2012 Healthcare Conference2012-08-27T20:30:00Z<![CDATA[SAN DIEGO, Aug. 27, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that Richard W. Pascoe, Somaxon's president and chief executive officer, will present at Stifel Nicolaus 2012 Healthcare Conference at the Four Seasons Hotel in Boston on Thursday, September 6, at 10:20 a.m. Eastern Time.]]>https://www.globenewswire.com/news-release/2012/08/07/275871/10001210/en/Somaxon-Pharmaceuticals-Reports-Second-Quarter-2012-Financial-Results.html?f=22&fvtc=4&fvtv=16016Somaxon Pharmaceuticals Reports Second Quarter 2012 Financial Results2012-08-07T20:00:00Z<![CDATA[Conference Call Scheduled Today at 4:30 p.m. ET (1:30 p.m. PT);
Simultaneous Webcast at http://investors.somaxon.com/eventdetail.cfm]]>https://www.globenewswire.com/news-release/2012/07/30/274727/263651/en/Somaxon-Pharmaceuticals-to-Report-Second-Quarter-2012-Results-and-Conduct-Conference-Call-on-Tuesday-August-7.html?f=22&fvtc=4&fvtv=16016Somaxon Pharmaceuticals to Report Second Quarter 2012 Results and Conduct Conference Call on Tuesday, August 72012-07-30T12:00:00Z<![CDATA[SAN DIEGO, July 30, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that it will release its second quarter financial results for the period ended June 30, 2012, on Tuesday, August 7, 2012 after the close of the U.S. financial markets. The Company will also conduct a conference call that same afternoon at 4:30 p.m. ET (1:30 p.m. PT) to discuss results and highlights of the second quarter of 2012.]]>https://www.globenewswire.com/news-release/2012/07/24/274322/263200/en/Somaxon-Pharmaceuticals-Completes-3-0-Million-Registered-Direct-Offering.html?f=22&fvtc=4&fvtv=16016Somaxon Pharmaceuticals Completes $3.0 Million Registered Direct Offering2012-07-24T20:35:00Z<![CDATA[SAN DIEGO, July 24, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that it has completed its previously announced registered direct offering of approximately 9.4 million shares of its common stock and warrants to purchase up to approximately 4.7 million shares of its common stock to institutional investors. Aggregate gross proceeds to the company were approximately $3.0 million, before deducting anticipated placement agent fees and expenses of approximately $0.3 million. The warrants will have an initial exercise price of $0.46 per share, will be exercisable commencing six months and one day from the date of issuance and will expire on the fifth anniversary of the initial exercise date. Roth Capital Partners acted as sole placement agent for the offering.]]>